MedPath

An international field study for the reliability and validity of the EORTC Sexual Health Questionnaire (EORTC SHQ-C22) for assessing sexual health in cancer patients.

Completed
Conditions
seksual problems after cancer treatment
Sexual health
sexuality
10027656
Registration Number
NL-OMON43354
Lead Sponsor
Medical University Graz
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
40
Inclusion Criteria

The study sample will be composed of a consecutive series of cancer patients who meet the study eligibility criteria in each participating centre. Study participants will be enrolled in four groups: Group A: Patients undergoing surgery alone Group B: Patients who receive chemotherapy and/or radiotherapy and/or endocrine therapies as first line treatment with curative intention Group C: Patients who receive palliative treatment (any treatment) Group D: Patients with no evidence of disease who have completed treatment for at least 6 months up to 5 years (test-retest) The SHQ-C22 will be used in patients from across all cancer sites and stages. Sampling will be on the basis of gender, age, primary cancer diagnosis and treatment. a) Histological confirmed diagnosis of cancer (primary, recurrent or metastatic disease) b) Any tumour site and stage c) Mentally fit to complete the questionnaires d) Able to understand the language of the questionnaires e) 18 years of age or above f) Patient is willing to give informed written consent

Exclusion Criteria

Patients participating in other QoL studies that might interfere with this study b) Patients who are unable to self-complete the questionnaires

Study & Design

Study Type
Observational non invasive
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<p>The primary endpoint of the study is to confirm the hypothesized scale<br /><br>structure of the EORTC SHQ-C22.</p><br>
Secondary Outcome Measures
NameTimeMethod
<p>Scale Structure, Reliability, Convergent validity, Known-group comparisons,<br /><br>Responsiveness to change analysis</p><br>
© Copyright 2025. All Rights Reserved by MedPath